We bring ideas to life
Government-backed Medical Research Commercialisation Fund makes first New Zealand investment in pharmaceutical company spun-out of the University of Auckland.
The Medical Research Commercialisation Fund (MRCF) today announces an investment of NZD$8 million in Series A funding for Kea Therapeutics Ltd., an early stage pharmaceutical company which is developing a new drug for the relief of severe pain.
The University of Auckland partners with the NBR for their RADAR publication, which identifies future wealth creators set to make a significant contribution to NZ’s economic success. See who made the list.
A culturally-adapted parenting programme for Māori families has increased parents’ confidence, reduced conflict between partners and improved children’s behaviour.
These results followed participation by the families in a four-hour programme. The Ministry of Health funded study was conducted by the University of Auckland and the Ngāti Hine Health Trust in Te Tai Tokerau, one of the largest Māori health providers in the country.
Winners of the fifth annual KiwiNet Research Commercialisation Awards, designed to celebrate commercialisation success within New Zealand’s universities and Crown Research Institutes, have been announced.
"We are very proud to have won two awards at the recent Kiwinet Awards, to win Deal of the Year and Research and Business Partnership award, demonstrates that our innovative, client led approach to commercialisation and research deliver great results that are recognised within the community." Will Charles, GM Technology Development.
Hopes to fight untreatable strains of gonorrhoea have risen after it emerged that a new vaccine against meningitis unexpectedly reduced the risk of people getting the sexually transmitted infection.
UniServices has signed a multi-million-dollar deal that will allow a significant increase in the number and quality of world class “disruptive” companies spun out of the university’s research and development.
It is part of an agreement that will see Auckland and the Group of Eight (Go8*) Australian universities together receive investment of “at least” NZ$215 million over 10 years to find and develop companies involved in “disruptive innovation” in areas such as digital medicine, new medical therapies and quantum computing.
The University of Auckland’s new Innovation Institute China (UAIIC) will provide unprecedented access to an extensive range of networks, research and funding opportunities in China.
The University of Auckland’s knowledge transfer company, UniServices, has established the institute in the Chinese city of Hangzhou. It is due to formally open in the first quarter of 2017 and will focus on collaboration.
The Innovation Institute will allow the University of Auckland, UniServices and its partners to:
UniServices and the University of Auckland are partnering with an American drug development company to launch a biotech start-up that will research novel cancer vaccines.
The new start-up, SapVax was formed by scientists from the University of Auckland and BioMotiv, an accelerator company in Cleveland, Ohio, that is part of a $300 million initiative for advancing medicine called The Harrington Project for Discovery & Development.
SapVax will develop a suite of first-in-class cancer vaccines based on a novel peptide platform technology.